| Literature DB >> 24957052 |
Wondmagegn Tamiru Tadesse1, Alemayehu Berhane Mekonnen, Wubshet Hailu Tesfaye, Yidnekachew Tamiru Tadesse.
Abstract
BACKGROUND: Patients on antiretroviral therapy have higher risk of developing adverse drug reactions (ADRs). The impact of ADRs on treatment adherence, treatment outcomes and future treatment options is quiet considerable. Thus, the purpose of this study was to describe the common self-reported ADRs and their impact on antiretroviral treatment.Entities:
Mesh:
Year: 2014 PMID: 24957052 PMCID: PMC4082293 DOI: 10.1186/2050-6511-15-32
Source DB: PubMed Journal: BMC Pharmacol Toxicol ISSN: 2050-6511 Impact factor: 2.483
Descriptive analysis of socio-demographic, clinical variables and health status of the participants, ART clinic, Gondar University Hospital, June 2012
| Education ( primary and above) | 287(74.7) |
| Work status (unemployed) | 149 (38.8) |
| Age (≤40 years) | 327(85.2) |
| Gender (female) | 257(66.9) |
| Marital status ( married) | 212 (55.2) |
| Residency (urban) | 346 (90.1) |
| Duration of ART ( ≤4 years) | 155(40.4) |
| Current CD4 level ( cells/mm3 ) | |
| < 200 | 47(12.2) |
| 200-350 | 134(34.9) |
| >350 | 203(52.9) |
| AZT/3TC/NVP | 154 (40.1) |
| TDF/3TC/NVP | 50 (13.0) |
| AZT/3TC/EFV | 48(12.5) |
| D4T/3TC/NVP | 44(11.5) |
| TDF/3TC/EFZ | 42 (10.9) |
| D4T/3TC/EFZ | 23(6.0) |
| Others | 23(6.0) |
| Non adherence | 14(3.6) |
| General health at the start of treatment | |
| Healthy | 50(13.0) |
| Mild to severely ill | 334 (87.0) |
| Increased | 345 (89.8) |
| Decreased | 9(2.3) |
| No change | 30(7.8) |
| Improved | 344(89.6) |
| Not improved | 40(10.4) |
| Increased | 323(84.1) |
| Decreased | 23(6.0) |
| No change | 38(10.0) |
| Increased | 81(21.1) |
| Decreased | 10(2.6) |
| No change | 293(76.3) |
Distribution of major reasons and documented ADRs responsible for treatment change (based on chart review), ART clinic, Gondar University Hospital, June 2012
| | |
| Due to ADRs | |
| Due to treatment failure | 10 (13.0) |
| Due to TB co-morbidity | 4 (5.0) |
| Due to pregnancy | 2 (3.0) |
| CNS symptoms | |
| Anemia | 10 (16.1) |
| Peripheral neuropathy | 9(14.5) |
| Skin rash | 8 (12.9) |
| Lipodystrophy | 7(11.3) |
| Weight loss | 4(6.5) |
| Stomach ache | 3 (4.8) |
| Hepatotoxicity | 3 (4.8) |
| Dental illness | 1 (1.6) |
Percent frequency out of the total number of patients (reasons for treatment change, N = 78; ADRs responsible for treatment change, N = 62). The most frequent reasons are highlighted in bold type.
95% CI, 0.68-0.88; p =0.00.
Most common self-reported adverse drug reactions of antiretroviral therapy, ART clinic, Gondar University Hospital, June 2012
| Nausea | 217 (56.5) |
| Headache | 211 (54.9) |
| Fever | 157 (40.9) |
| Vomiting | 147 (38.3) |
| Lethargy/fatigue | 131(34.1) |
| Loss of appetite | 130 (34) |
| Insomnia | 102 (26.6) |
| Depression/stress | 99 (25.8) |
| Skin rash | 85 (22.1) |
| Night mare | 72 (18.8) |
| Diarrhea | 41 (10.7) |
| Oral ulceration/dry mouth | 35 (9.1) |
| Anxiety | 23 (6.3) |
| Others** | 10 (2.6) |
*number of frequency and percent proportions, total number of participants (N = 384).
**includes tingling in hands or feet, anemia.
Logistic regression analysis of selected variables and adverse drug reactions to ART, ART clinic, Gondar University Hospital, June 2012
| | |||||
| ≤ 40 years | 327 | 192(58.7) | 1 | | |
| >40 years | 57 | 37(64.9) | 1.28(0.69, 2.38) | 0.44 | |
| | |||||
| Female | 257 | 152(59.1) | 1 | | |
| Male | 127 | 77(60.6) | 1.06 (0.69, 1.64) | 0.78 | |
| | |||||
| Illiterate | 97 | 58(59.8) | 1 | | |
| ≥primary | 287 | 171(59.6) | 0.92 (0.58, 1.46) | 0.72 | |
| | |||||
| Employed | 149 | 78(52.3) | 1 | | 1 |
| Non-employed | 235 | 151(64.2) | 1.82 (1.17, 2.84) | <0.01 | 1.76 (1.15, 2.70)a |
| | |||||
| Married | 212 | 121(57.1) | 1 | | |
| Non- married | 172 | 108(62.8) | 1.16 (0.75, 1.82) | 0.50 | |
| | |||||
| Urban | 346 | 211(61.0) | 1 | | |
| Rural | 38 | 18(43.4) | 0.58(0.28, 1.18) | 0. 14 | |
| | |||||
| ≤4 years | 155 | 85(54.8) | 1 | | |
| >4 years | 229 | 144(62.9) | 1.39 (0.92, 2.21) | 0.11 | |
| | |||||
| Yes | 78 | 42(53.8) | 1 | | |
| No | 306 | 187(61.1) | 1.35(0.82,2.22) | 0.24 | |
| | |||||
| ≤350 | 181 | 107(59.1) | 0.96(0.64, 1.44) | 0.85 | |
| >350 | 203 | 122(60.1) | 1 | | |
| | |||||
| AZT backbone | 204 | 122(59.8) | 1.01(0.67, 1.53) | 0.94 | |
| Non-AZT backbone | 180 | 107(59.4) | 1 | | |
| | |||||
| Yes | 370 | 223(60.3) | 1 | | |
| No | 14 | 6(42.8) | 0.50(0.17, 1.45) | 0.2 | |
| | |||||
| ≤1 month | 212 | 140(66.0) | 1.81(1.20, 2.74) | | 1.95(1.28,2.98)b |
| >1 month | 172 | 89(51.7) | 1 | <0.01 | 1 |
*Percent frequency that refers to the total number of patients (N = 384). **Number and proportion of patients’ self-reporting 3 or more adverse drug reactions. ***Values represent odds ratio (OR) at 95% confidence interval. †Values represent adjusted odds ratio (AOR) at 95% confidence interval, ap = 0.01, bp = 0.001.
Impacts of self-reported ADRs on perception of treatment and social interaction, ART clinic, Gondar University Hospital, June 2012
| | | | | | | | | | | |||
| Decided to skip medication due to ADRs* | 10 (2.6) | 0.54 | 0.51 | 0.35 | 0.55 | 0.26 | 0.48 | 0.20 | 0.21 | 0.42 | 0.78 | 0.26 |
| Consider ART unsuccessful due to ADRs** | 114 (31.0) | 1.43 | 0.10 | 7.42b | 5.00a | 29.53c | 25.93 c | 14.47 c | 24.43c | 1.43 | 13.63c | 13.70c |
| | | | | | | | | | | |||
| Perceive that people avoid them due to observed ADRs** | 21 (32.9) | 5.68 a | 0.76 | 11.97c | 12.7c | 28.13c | 26.67 c | 18.28 c | 23.15c | 3.19a | 8.45b | 14.94c |
| Tend to reduce/avoid social interaction because of ADRs** | 119 (32.2) | 2.11 | 0.26 | 9.87 c | 7.96b | 33.20 | 26.67c | 20.88 c | 3.40c | 1.87 | 8.45b | 6.70 c |
| Perceive family members avoid them when ADRs occurred ** | 57 (15.4) | 0.99 | 3.35a | 2.19 | 0.06 | 0.08 | 1.01 | 0.45 | 3.40a | 0.03 | 0.99 | 6.70b |
| Talk to family members about ADRs as it appears** | 296 (80.0) | 14.32c | 10.24c | 5.92 b | 7.73b | 4.34a | 2.84 | 0.61 | 2.21 | 0.31 | 0.01 | 0.62 |
n = 384. *Fishers exact test, **chi-square test was used to assess associations. asignificant at a level of p < 0.05, bsignificant at a level of p < 0.01, csignificant at a level of p < 0.001. OU/DM, oral ulceration or dry mouth.